Thus, pre-clinical studies have provided four independent lines of evidence (complementation assays using xenografts; a NfibR388K knock-in mouse, a CARM1 conditional knockout mouse, and CARM1 inhibitors) supporting CARM1 as a potential therapeutic target for SCLC patients. Here, CARM1 is linked to small cell lung carcinoma.